ERBB2 and cancer: Following this observation, in the present study we demonstrate that the pharmacological interception of the ErbB2-HSF1-mutp53 feed-forward loop by the FDA-approved dual ErbB2/EGFR inhibitor lapatinib destabilizes mutp53 protein in cancer cells.